Wednesday - May 7, 2025
DURHAM, N.C. / Aug 24, 2023 / Business Wire / Zoetis:
NEWS FACTS
ZOETIS IN DURHAM
QUOTES
“We are thrilled to celebrate our new building in Durham, where our research and development team dedicated to diagnostics and engineering is based. As the innovation leader in animal health, it’s important to us to be part of the dynamic technology community here in Durham,” said Rob Polzer, Executive Vice President and President of Research and Development at Zoetis. “I am optimistic about our ability to continue to innovate in diagnostics and biodevices to meet the needs of our customers and the pets and livestock they care for.”
“Our colleagues in Durham have a long history of purpose-driven innovation that transforms animals’ lives – from our Embrex biodevice that’s helped automate and revolutionize poultry hatcheries in the U.S. and markets around the world to our growing focus on diagnostics to help veterinarians deliver accurate results more quickly to pet owners,” said Kristin Peck, CEO Zoetis. “Our continued investment in innovation, research and development, and manufacturing helps distinguish us as the global leader in animal health.”
ABOUT ZOETIS
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.
Last Trade: | US$155.99 |
Daily Change: | 6.12 4.08 |
Daily Volume: | 4,378,795 |
Market Cap: | US$70.380B |
May 06, 2025 February 14, 2025 February 13, 2025 February 04, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load